Compact Accelerator-Based Production of Carrier-free 177 Lu From 18 MeV D + D^{+} on [ 176 Yb]Yb 2 O 3
Austin A. Morris, Tianhao Wei, Zhi Wang, Ying Xia, Meiyun Han, Yuanrong Lu · 2025
Read Compact Accelerator-Based Production of Carrier-free 177 Lu From 18 MeV D + D^{+} on [ 176 Yb]Yb 2 O 3 by Austin A. Morris, Tianhao Wei, Zhi Wang, Ying Xia, Meiyun Han, Yuanrong Lu (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2503-05608.txt.
Introduction
Austin Morris and co-authors design a compact accelerator to make a cancer treatment isotope without a reactor, in work from twenty twenty-five. The isotope, lutetium-177, is used in approved targeted radiation drugs. Reactor supply is the norm, so a small machine source could widen access.
Their plan fires deuterons at an enriched ytterbium oxide target with a linear accelerator about twelve metres long. Lab and simulated yield curves feed the output math. A five day run could make more than a milligram of the isotope at high activity. After two days of processing, purity passes a high bar with no carrier added. The authors call the route viable for clinical use.
Catalog record
| CREATOR | Austin A. Morris, Tianhao Wei, Zhi Wang, Ying Xia, Meiyun Han, Yuanrong Lu |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2503-05608
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Compact Accelerator-Based Production of Carrier-free 177 Lu From 18 MeV D + D^{+} on [ 176 Yb]Yb 2 O 3 Austin A. Morris, Tianhao Wei, Zhi Wang, Ying Xia, Meiyun Han, Yuanrong Lu Abstract We use experimental and simulated excitation functions to estimate the yield of deuteron activations on a [ 176 Yb]Yb 2 O 3 target enriched to 99%. Subsequent calculations are used to determine the production of radiotherapeutic 177 Lu according to a 10 mA, 18 MeV D + D^{+} compact linear accelerator. The design comprises a single radio-frequency quadrupole accelerator (RFQ) and seven drift tube linacs (DTLs) that achieve a beam efficiency of 98.5% over a length of 12 m 12\,\text{m} . Our results show that a 5-day irradiation can yield more than 1 1 mg of 177 Lu, exceeding 4.4 4.4 TBq. After a 2 day processing period, it is estimated that the sample will have a radiopurity greater than 99.8% (carrier-free). Given recent EMA and FDA approvals of 177 Lu-DOTATATE and 177 Lu-PSMA-617, our results confirm the viability of accelerator-based 177 Lu production and provide a promising clinical alternative to reactor-based methods. Preprint: APS/123-QED I Introduction Several studies have reported on the potential of 177 Lu as an in vivo radioisotope useful for the treatment of metastatic lesions and neuroendocrine cancers [ 1 , 2 , 3 ] . 177 Lu is a desirable radioisotope due to its intermediate half-life ( t_{1/2} = 6.65 days) and moderate energy release. It beta decays to a stable ground state of 177 Hf (78.6% of the time), to a 0.25 MeV excited state (9.2%), and to a 0.32 MeV excited state (12.2%). Compared to other therapeutic radioisotopes (such as 90 Y, 131 I, and 186 Re), the localized beta particles produced by 177 Lu have a smaller mean penetration range in tissue of approximately 0.62\,\text{mm} [ 4 ] . Since the excited states also produce low-energy gamma rays—113 keV (6.6%) and 208 keV (11%)—PET image-guided, theranostic (therapy and diagnosis) treatments are possible [ 5 , 6 , 7 , 8 ] . Furthermore, 177 Lu can be combined with other radionuclides, such as 67 Cu and 90 Y, for tandem use [ 9 ] . For targeted radiotherapy, lutetium can be added to a variety of molecular carriers, antibodies, and peptides to preferentially accumulate in cell receptors over expressed on tumor surfaces [ 1 , 6 , 10 ] . Examples include prostrate-specific membrane antigen (PSMA) and peptide receptor radionuclide therapy (PRRT). An amino acid transporter protein, PSMA is expressed 100 to 1000 times more in prostate cancer than in normal tissue [ 11 , 4 , 12 , 13 , 14 ] . Successful treatments of patients with metastatic lesions and prostrate cancer have led to recent approval by the EMA and FDA of 177 Lu-DOTATATE and 177 Lu-PSMA-617 for neuroendocrine cancers and PSMA-positive metastatic castration-resistant prostrate cancer (mCRPR) [ 9 , 15 , 10 , 16 , 11 , 12 , 17 , 18 , 19 ] . Early results indicate that 177 Lu-based drugs have limited side effects and a better toxicity profile compared to other radionuclides [ 13 , 17 , 14 ] . Consequently, the demand for 177 Lu has increased in recent years, with a particular focus on developing production facilities that are better equipped to meet treatment requirements. In this study, we present the general design of an 18 MeV D^{+} linear accelerator (linac) optimized for the production of high purity 177 Lu. We develop a model based on experimental [ 2 , 20 , 21 ] and simulated [ 22 ] excitation functions to optimize the target width and yield of deuteron activations from a Yb 2 O 3 target enriched to 99% 176 Yb. Based on our accelerator and target parameters, the expected radiopurity of carrier-free 177 Lu is estimated to exceed 99.8% after a 5-day irradiation. Longer irradiations offer similar radiopurity and produce 1 to 2 mg of 177 Lu. Compared to previous studies using reactor-based production, we show that accelerator-based production generates less target burn-up, reduced waste, higher radiopurity, and competitive overall yield. Since an accelerator facility is generally safer and easier to maintain than a high flux reactor, the design is expected to better meet therapeutic production demand. II Accelerator Design Currently, 177 Lu is most commonly produced by neutron activation in a high flux reactor [ 1 , 23 ] . This involves either irradiating an ordinary lutetium target or an enriched 176 Yb target (12.9% natural abundance), giving the reactions {}^{176}\text{Lu}\,+\,n\, \displaystyle\longrightarrow \,{}^{177}\text{Lu}\,+\,{\gamma}\;\;\text{(direct),} (1) {}^{176}\text{Yb}\,+\,n\, \displaystyle\longrightarrow \,{}^{177}\text{Yb}\,+\,\gamma\;\;\text{(indirect)}. (2) In the indirect route, 177 Yb ( t_{1/2} = 1.91 h) is produced, which quickly beta-decays into 177 Lu. The drawbacks of reactor-based production include the high thermal neutron flux required ( 10^{14} n/cm 2 /s) as well as the 2.6% natural abundance of 176 Lu ( t_{1/2}\sim 4\times 10^{10} y). For both direct and indirect production routes, high neutron activation cross sections lead to significant target burn-up and radioactive waste, which also reduces the specific activity of 177 Lu [ 16 , 24 ] . The waste products include {}^{174\text{g}} Lu ( t_{1/2}=3.31 y), {}^{174\text{m}} Lu ( t_{1/2}=120.9 d), {}^{176\text{m}} Lu ( t_{1/2}=3.66 d), and {}^{177\text{m}} Lu ( t_{1/2}=160.4 d) [ 25 ] . Due to these contaminants, target waste and patient urine must be disposed of in a dedicated waste management facility [ 5 ] . Large amounts of stable 175 Lu in the target also reduce the specific activity of the desired 177 Lu product. By comparison, accelerator-based production methods generate one-tenth as much nuclear waste, require lower maintenance costs (including decommissioning), and have a better safety profile [ 26 ] . Proton beams are inadequate for lutetium production as a result of small Yb/Lu activation cross sections. However, deuteron beams, with moderate stopping power and high neutron-stripping cross sections, provide an ideal choice [ 27 ] . Similar to before, 177 Lu is produced indirectly by deuterons through {}^{176}\text{Yb}\,+\,d\, \displaystyle\longrightarrow \,{}^{177}\text{Yb}\,+\,p\;\;(Q=3.34\text{ MeV}) (3) reactions, at a rate about nine times greater than for direct 176 Yb( d,n ) 177 Lu reactions [ 28 ] . The 176 Yb( d,p ) 177 Yb cross section begins to increase around 5 MeV before reaching a peak of approximately 230 mb at 12.5 MeV, as shown in Figure 1 . Figure 1: Experimental [ 2 , 20 , 21 , 29 ] and simulated [ 25 ] 176 Yb( d,p ) 177 Yb cross section data. Due to the large underestimation by TENDL-2023 for this reaction, we instead use an interpolation of the Hermanne (2006) and Manenti (2010) data for subsequent calculations. For higher deuteron energies, 174g+m Lu production cross sections increase [ 9 ] . Hence, a higher purity of 177 Lu is obtained for deuteron beam energies E<20 MeV [ 2 ] . In this range, metastable 176m Lu is produced but decays rapidly, while the production of longer-lived 177m Lu is negligible due to its high spin value J^{\pi}=23/2^{-} [ 30 ] . Figure 2: Side-view schematic of the RFQ-DTL components, including water cooling ports, vacuum pumps, power couplers, and tuners. Labels correspond to: (1) microwave waveguide, (2) ECR (Electron Cyclotron